Non-TBI and Alkylator-free Conditioning for Allogeneic Bone Marrow Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
N/A
30 Years
Both
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
Trial Information
Non-TBI and Alkylator-free Conditioning for Allogeneic Bone Marrow Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents
with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia.
DC is part of a spectrum of telomere biology disorders, which include some forms of
inherited idiopathic aplastic anemia, myelodysplastic syndrome, and pulmonary fibrosis and
the congenital diseases Hoyeraal-Hreidarsson syndrome and Revesz syndrome. Progressive bone
marrow failure (BMF) occurs in more than 80% of patients under 30 years of age and is the
primary cause of morbidity and mortality, followed by pulmonary failure and malignancies.
Allogeneic hematopoietic cell transplantation (HCT) is curative for the hematological
defects, but several studies have demonstrated poor outcomes in DC patients due to increased
early and late complications. A predisposition to pulmonary failure, vascular disease and
secondary malignancies may contribute to the high incidence of fatal complications following
HCT in DC patients, and provides an impetus to reduce exposure to chemotherapy and
radiotherapy in preparative regimens. Recent studies suggest that fludarabine-based
conditioning regimens provide stable engraftment and may avoid the toxicities seen after HCT
for DC, but studies to date are limited to case reports, retrospective studies and a single
prospective trial. In this study, we propose to prospectively evaluate the efficacy of a
fludarabine- and antibody-based conditioning regimen in HCT for DC patients, with the goals
of maintaining donor hematopoiesis and transfusion independence while decreasing early and
late complications of HCT for DC.
Inclusion Criteria:
- Bone marrow cellularity: hypocellular for age
- Moderate or severe aplastic anemia defined by one of the following: peripheral blood
neutrophils < 0.5 x 10^9/L; platelets < 30 x 10^9/L or platelet transfusion
dependence; reticulocytes < 50 x 10^9/L in anemic patients or red cell transfusion
dependence
- Diagnosis of dyskeratosis congenita based on clinical triad of abnormalities of skin
pigmentation, nail dystrophy, oral leukoplakia; OR one of clinical triad and presence
of two or more associated features; OR a pathogenic mutation in DKC1,TERC, TERT,
NOP10, NHP2, TCAB1, TINF2, CTC1 as reported by a CLIA-approved laboratory; OR
age-adjusted mean telomere length < 1%ile in peripheral blood lymphocytes as reported
by a CLIA-approved laboratory; OR Hoyeraal-Hreidarsson syndrome; OR Revesz syndrome
- Availability of a related or unrelated donor with a 7/8 or 8/8 match for HLA-A, B, C,
and DRB1.
- Patient and/or legal guardian must be able to sign informed consent.
- Matched unrelated donor must consent to provide a marrow allograft.
- Diagnosis of Fanconi anemia must be excluded by mitomycin C or diepoxybutane
chromosomal breakage testing on peripheral blood at a CLIA-approved laboratory (not
required for patients with a genetic mutation consistent with DC)
- Adequate renal function with glomerular filtration rate equal to or greater than 30
ml/min/1.73 m2
Exclusion Criteria:
- Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow
examination.
- Karnofsky/Lansky performance status < 40%.
- Uncontrolled bacterial, viral or fungal infections.
- Positive test for the human immunodeficiency virus (HIV).
- Pregnancy or breastfeeding.
- Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab,
cyclosporine, or mycophenolate mofetil.
- Positive patient anti-donor HLA antibody, which is deemed clinically significant.
- Prior allogeneic marrow or stem cell transplantation.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Day +100 Post-transplant Survival
Outcome Description:
To determine feasibility, in terms of the proportion of patients who survive to Day+100 post-transplant, of a reduced intensity conditioning regimen in allogeneic HCT for BMF due to DC.
Outcome Time Frame:
100 days post bone marrow infusion
Safety Issue:
Yes
Principal Investigator
Suneet Agarwal, MD, PHD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Boston Children's Hospital
Authority:
United States: Institutional Review Board
Study ID:
12-950
NCT ID:
NCT01659606
Start Date:
July 2012
Completion Date:
October 2032
Related Keywords:
- Dyskeratosis Congenita
- Hoyeraal Hreidarsson Syndrome
- Revesz Syndrome
- Aplastic Anemia
- dyskeratosis congenita
- bone marrow failure
- aplastic anemia
- bone marrow transplantation
- reduced intensity conditioning
- campath
- fludarabine
- telomere
- Anemia
- Anemia, Aplastic
- Pancytopenia
- Dyskeratosis Congenita
- Bone Diseases, Metabolic
- Fetal Growth Retardation
- Mental Retardation
- Microcephaly
Name | Location |
|---|---|
| Boston Children's Hospital | Boston, Massachusetts 02115 |
